# Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1

> **NCT02390466** · PHASE1,PHASE2 · UNKNOWN · sponsor: **InnaVirVax** · enrollment: 15 (estimated)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** VAC-3S

## Key facts

- **NCT ID:** NCT02390466
- **Lead sponsor:** InnaVirVax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02390466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02390466, "Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02390466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*